Our established novel distance (cut-off) score based on ESPL1, PTTG1 and PTTG1IP gene expression levels can serve as a predictor of TKI non-response and a tool in risk stratification of CML patients before initiation of TKI first-line treatment. This evidence concerns the gene ESPL1 and chronic myelogenous leukemia, BCR-ABL1 positive.